Safranal
Based on 6 publication(s) in Google Scholar
Safranal is an orally active main component of Saffron (Crocus sativus) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research.
For research use only. We do not sell to patients.
- Purity: 97.10%
- CAS No.: 116-26-7
- Formula: C10H14O
- Molecular Weight:150.22
-
Storage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Safranal
More- Phytomedicine. 2025 Dec 5:150:157675. [Abstract]
- Phytomedicine. 2023 Jun:114:154739. [Abstract]
- PLoS Biol. 2024 Jun 27;22(6):e3002672. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 31. [Abstract]
- Curr Med Sci. 2025 Apr;45(2):288-300. [Abstract]
- bioRxiv. 2024 Apr 3:2023.06.02.542933. [Abstract]
Customer Validation & Images
-
IF
-
WB
-
RT-PCR
Biological Activity
Safranal (10-50 μM; for 1 h) dose-dependently decreases LPS-induced iNOS and COX-2 levels in both RAW264.7 cells and BMDMs[1].
Safranal (10-50 μM; for 1 h) inhibits cytokine IL-6 and TNF-α production and mRNA expression in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells[1].
Safranal (10, 50 μM; for 1 h followed by stimulation with 1 μg/ml of LPS for 30 min) inhibits the nuclear translocation of NF-κB and AP-1 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells and bone marrow-derived macrophages (BMDMs)
-
Concentration:10, 50 μM
-
Incubation Time:For 1 h prior to lipopolysaccharide (LPS) stimulation (1 µg/ml)
-
Result:Dose-dependently decreased LPS-induced iNOS and COX-2 levels in both RAW264.7 cells and BMDMs.
Inhibited the phosphorylation of MAPK pathway proteins extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38.
Inhibited NF-κB pathway proteins IKKα/β and IκBα and the degradation of IκBα.
-
Cell Line:RAW 264.7 cells
-
Concentration:10, 50 μM
-
Incubation Time:For 1 h followed by stimulation with LPS (1 μg/ml) for 24 h
-
Result:Inhibited cytokine IL-6 and TNF-α production and mRNA expression in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice (18-20 g) (DSS-induced colitis mice)[1]
-
Dosage:200, 500 mg/kg
-
Administration:PO; for 7 days
-
Result:Caused a slight restoration of colon length and percentage of weight loss, and the DAI score is significantly low.
Chemical Information
-
CAS No. 116-26-7
-
Appearance Liquid (Density: 0.966 g/cm3 )
-
Molecular Weight 150.22
-
Formula C10H14O
-
Color Light yellow to yellow
-
SMILES
O=CC1=C(C)C=CCC1(C)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Safranal accelerates diabetic wound healing by suppressing ferroptosis through modulation of transcription factor Forkhead Box O3. [Abstract]2025 Dec 5:150:157675. PMID: 41385950 -
Phytomedicine
Safranal inhibits estrogen-deficiency osteoporosis by targeting Sirt1 to interfere with NF-κB acetylation. [Abstract]2023 Jun:114:154739. PMID: 37004404
Safranal purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jun:114:154739. [Abstract]
Safranal (Saf; 5, 10, 20 μM; 6 days) suppresses RANKL-increased numbers of TRAcP-positive multinucleated osteoclasts in a concentration-dependent manner, in BMMs.
Safranal purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jun:114:154739. [Abstract]
Safranal (Saf; 20 μM; 1, 3, 5 days) inhibits RANKL-induced overproduction of osteoclast-related osteo-resorptive proteins (V-ATPase-d2 and CTSK) in BMMs.
Safranal purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jun:114:154739. [Abstract]
Safranal (Saf; 5, 10, 20 μM; 6 days) inhibits RANKL-induced overproduction of osteoclast-related mRNAs (Acp5, CTSK, Atp6v0d2, c-Fos) in BMMs.
-
PLoS Biol
2024 Jun 27;22(6):e3002672. PMID: 38935621 -
Naunyn Schmiedebergs Arch Pharmacol
Safranal restores RUNX3-mediated immunoregulation by inhibiting the NLRP3 inflammasome in allergic asthma. [Abstract]2025 Mar 31. PMID: 40163148 -
Curr Med Sci
Safranal Ameliorates Renal Damage, Inflammation, and Podocyte Injury in Membranous Nephropathy via SIRT/NF-κB Signalling. [Abstract]2025 Apr;45(2):288-300. PMID: 40035996 -
bioRxiv
An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]2024 Apr 3:2023.06.02.542933. PMID: 37333363
Solvent & Solubility
DMSO : 100 mg/mL (665.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (665.69 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (16.64 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (16.64 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (16.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (466 KB)
- English - EN (466 KB)
- Français - FR (466 KB)
- Deutsch - DE (466 KB)
- Norwegian - NO (466 KB)
- Español - ES (466 KB)
- Swedish - SV (466 KB)
- Italian - IT (466 KB)
- Portuguese - PT (466 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 6.6569 mL | 33.2845 mL | 66.5690 mL | 166.4226 mL |
| 5 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL | 33.2845 mL | |
| 10 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL | 16.6423 mL | |
| 15 mM | 0.4438 mL | 2.2190 mL | 4.4379 mL | 11.0948 mL | |
| 20 mM | 0.3328 mL | 1.6642 mL | 3.3285 mL | 8.3211 mL | |
| 25 mM | 0.2663 mL | 1.3314 mL | 2.6628 mL | 6.6569 mL | |
| 30 mM | 0.2219 mL | 1.1095 mL | 2.2190 mL | 5.5474 mL | |
| 40 mM | 0.1664 mL | 0.8321 mL | 1.6642 mL | 4.1606 mL | |
| 50 mM | 0.1331 mL | 0.6657 mL | 1.3314 mL | 3.3285 mL | |
| 60 mM | 0.1109 mL | 0.5547 mL | 1.1095 mL | 2.7737 mL | |
| 80 mM | 0.0832 mL | 0.4161 mL | 0.8321 mL | 2.0803 mL | |
| 100 mM | 0.0666 mL | 0.3328 mL | 0.6657 mL | 1.6642 mL |
Powered by Bioz